The Huge Burden Of Heart Failure Disease
After discharge from a Heart Failure hospitalization, patients are at an unacceptably high risk of recurrent hospitalizations or death.
- One major origin of post discharge events is the residual patient congestion that is not optimally alleviated at discharge.1
- In fact, many patients leave hospital before their diuretic therapy is optimized.
- Another important fact is that patients are discharged before lifesaving renin angiotensin antagonists and mineralocorticoid receptor antagonists could be optimized to reach the highest tolerable doses.2
Optimizing heart failure patient treatment at home by using:
- Artificial Intelligence
- Data analysis
Guidelines recommend optimizing pharmacotherapy to improve outcomes for patients with heart failure (grade 1, level of evidence A)
Optimizing medications belonging to the RAAS inhibitor class (ACE-Is, ARBs and MRAs) have been proven to improve survival and reduce hospitalizations in patients with heart failure.2 In addition, optimizing diuretics reduces volume overload, eases the signs and symptoms of pulmonary congestion and keeps patients out of hospital.2
The concerns for raising serum potassium levels, worsening renal function, or inadequate decongestion limit the way these medicines are utilized and dosed.3 Complicating the management of patients with heart failure is the fact that physicians do not have simple, patient-friendly tools to easily keep track of these issues with their patients at home.
We know that optimizing care through disease management programs improves outcomes in patients with heart failure. Up until recently, the focus has been on monitoring pulmonary congestion so that physicians can
optimize diuretic doses and reduce admissions.4
But this is only part of the solution ... We also need to be monitoring serum potassium and renal function so that physicians can optimize not just the dose of a diuretic, but also optimize doses of ACE-I, ARB or MRA. With such a complete view of the status of their HF patient overtime, physicians would feel safe and confident so as to optimize medication precisely to each patient status.
If there was a way to reliably, simply and cost-effectively monitor serum potassium, renal function and the degree of congestion in our heart failure patients at home, could we then optimize the use of these life-saving medicines? With a more comprehensive approach like this, we may be able to reduce not just hospital readmissions, but we may also be able to improve the quality of life and survival of HF patients.
Board of directors
Chief Executive Officer
Maurice BerengerChief Executive Officer
Guilhem HenrionChief Technical Officer
Julie PapillonOperations Director
Daphné LaporteQRA Manager
Fengjuan WANGInnovation Manager
Moez KarouiCloud Application Manager
Yohann ThomasR&D manager
David RabaudIndustrialisation project leader
Gabriel LemercierR&D project leader
David LefebvreIndustrialization Manager
Join our team
We are recruting to expand the team competences – Send your application!
We’re here to help and answer any question you might have. We look forward to hearing from you.
Operation DepartementBioparc 3, 850 Bd Sébastien Brant, 67400 Illkirch-Graffenstaden, FRANCE
Finance & Admin11 Rue Teheran, 75008 Paris, FRANCE